Michael J. Elmore

Salisbury, ENG SP40JG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

A full-length 16S survey using Nanopore sequencing to uncover the bacterial microbiome in Ixodes ricinus ticks from a single UK woodland, collected across three springs (2019-2021).

A full-length 16S survey using Nanopore sequencing to uncover the bacterial microbiome in Ixodes ricinus ticks from a single UK woodland, collected across three springs (2019-2021).

Journal: Ticks and tick-borne diseases
Published: March 06, 2025

Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Journal: The Journal of general virology
Published: July 26, 2023

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Journal: The Journal of general virology
Published: July 11, 2023

Linked Mutations in the Ebola Virus Polymerase Are Associated with Organ Specific Phenotypes.

Linked Mutations in the Ebola Virus Polymerase Are Associated with Organ Specific Phenotypes.

Journal: Microbiology spectrum
Published: March 22, 2023

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

Journal: ACS central science
Published: October 21, 2021

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.

Journal: Nature communications
Published: May 27, 2021

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Journal: Nature structural & molecular biology
Published: February 04, 2021

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Journal: Nature structural & molecular biology
Published: October 16, 2020

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19.

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19.

Journal: Nature communications
Published: September 06, 2020

Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.

Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.

Journal: British journal of pharmacology
Published: July 13, 2020

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Journal: Nature structural & molecular biology
Published: May 21, 2020

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.

Journal: Nature communications
Published: May 05, 2020
Showing 1-12 of 18

Last Updated: 09/26/2026